DAXOR CORP Stock Price, News & Analysis

Daxor Corporation (NYSE: DXR) announced that CEO Michael Feldschuh will present at the H.C. Wainwright BioConnect Investment Conference from January 11-14, 2021. He will discuss Daxor's innovative BVA-100® blood test, which has been used in over 50,000 assessments for various medical conditions, including heart failure. The company is also conducting a multi-center trial on COVID-19 and has contracts with the U.S. Department of Defense for advanced Blood Volume Analyzers.

Daxor Corporation (NYSE: DXR) has announced new acquisitions of its BVA-100® Blood Volume Analyzer by major medical centers, enhancing its presence in heart failure treatment. A leading Northeast academic center has integrated the device into inpatient protocols, while a Midwest clinic is utilizing it for outpatients. Additionally, three hospitals have renewed support agreements, reflecting the technology's value. The BVA-100® offers a cost-effective solution for fluid management, showing 80% lower costs compared to traditional therapies, and an average life-extension of 2.32 quality-adjusted life years.

Daxor Corporation (NYSE: DXR) announces that CEO Michael Feldschuh will present at the virtual 2020 LD MicroCap Main Event on December 14, 2020, at 10:40 AM ET. He will discuss the company's recent research on the BVA-100^® blood test, focusing on its cost-effectiveness and benefits for heart failure patients. This event features a new format where presentations are followed by Q&A sessions. Interested investors can contact Bret Shapiro at COREIR for more information.

Daxor Corporation (NYSE: DXR) announced a collaboration with Wake Forest Baptist Health for an ongoing trial to treat COVID-19 patients using its BVA-100 technology. The participation of Wake Forest School of Medicine underscores the significance of Daxor's blood volume measurement in understanding COVID-related volume derangements. Daxor's BVA test is the first FDA-cleared diagnostic for assessing blood volume status and capillary leak rates, which are associated with higher mortality. Prior clinical trials revealed a 66% reduction in ICU mortality when utilizing BVA testing.

Daxor Corporation (NYSE: DXR) announces Oregon Health & Science University (OHSU) as a second site for a COVID-19 clinical trial using its Blood Volume Analyzer (BVA) technology. This partnership follows the earlier collaboration with NYU Langone Health. The BVA-100 is FDA-cleared and quantifies blood components, aiding in patient treatment strategies. The trial aims to investigate the implications of COVID-19 as an endothelial disease, with findings from previous studies indicating significant reductions in ICU mortality. The study is led by Dr. Martin A. Schreiber at OHSU.

Daxor Corporation (NYSE: DXR) will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on October 13, 2020, at 3:00 PM ET. President and CEO Michael Feldschuh will provide insights on the company, including recent research from the Heart Failure Society of America, highlighting the BVA-100® blood test's cost-effectiveness and its potential to enhance patient lifespan in heart failure.

A Q&A session will follow the presentation. For more details, visit microcaprodeo.com.

Daxor Corporation (NYSE: DXR) recently presented new findings at the Heart Failure Society of America’s Annual Scientific Meeting regarding its BVA-100^® blood test, which measures anemia in heart failure patients. The study revealed that 62% of hospitalized heart failure patients suffer from true anemia, often undetected by standard tests. Daxor's BVA-100^® can significantly improve patient outcomes, reducing 30-day mortality by 82% and readmissions by 56%. The company is also developing next-gen measurement technologies under contracts with the US Department of Defense.

Daxor Corporation (NYSE: DXR) presented new data on the cost-effectiveness of its BVA-100 blood volume analysis technology for treating heart failure at the Heart Failure Society of America’s Annual Scientific Meeting 2020. The study found an incremental cost-effectiveness ratio (ICER) of $10,200, which is significantly lower than other therapies. This leads to an average life extension of 2.32 quality-adjusted life years (QALYs). Daxor's technology is noted for improving patient outcomes while being economically advantageous for healthcare systems.

Daxor Corporation (NYSE: DXR) announces new data from the Mayo Clinic demonstrating that its Blood Volume diagnostic test, BVA-100, significantly outperforms the common weight loss metric in assessing heart failure treatment progress. Presented at the HFSA Annual Scientific Meeting 2020, the study highlights that traditional weight loss does not predict clinical outcomes, while Daxor's technology has been shown to reduce heart failure mortality by over 80% and readmissions by over 56%. Daxor aims to integrate its technology into standard practice to enhance patient care.